{"id":41696,"date":"2025-09-17T15:07:33","date_gmt":"2025-09-17T07:07:33","guid":{"rendered":"https:\/\/flcube.com\/?p=41696"},"modified":"2025-09-17T15:11:26","modified_gmt":"2025-09-17T07:11:26","slug":"hisun-pharma-secures-china-rights-to-ascentawits-first%e2%80%91in%e2%80%91class-drug-ast%e2%80%913424","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=41696","title":{"rendered":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424"},"content":{"rendered":"\n<p><strong>Zhejiang Hisun Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/600267:SHA\">SHA: 600267<\/a>)<\/strong> announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with <strong>Shenzhen Ascentawits Pharmaceuticals Ltd.<\/strong> Under the deal, Hisun will introduce <strong>AST\u20113424<\/strong>, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Up\u2011front &amp; Milestone Payments<\/strong><\/td><td>Up to <strong>RMB\u202f240\u202fmillion<\/strong> in total, paid to Ascentawits upon signing and as development milestones are achieved.<\/td><\/tr><tr><td><strong>Sales Royalties<\/strong><\/td><td>Annual royalties based on a specified percentage of net sales after the product receives first marketing approval (including conditional approval) in the partnership regions.<\/td><\/tr><tr><td><strong>Sales Milestones<\/strong><\/td><td>Additional payments tied to net\u2011sales thresholds reached each year.<\/td><\/tr><tr><td><strong>Strategic Platform Collaboration<\/strong><\/td><td>Hisun will partner with Ascentawits on the <strong>AKR1C3 enzyme\u2011activation platform<\/strong>. Ascentawits will use its platform to develop and advance Hisun\u2011designated drugs to clinical\u2011trial approval in Mainland China.<\/td><\/tr><tr><td><strong>Platform Up\u2011front Payment<\/strong><\/td><td><strong>RMB\u202f5\u202fmillion<\/strong> paid immediately to Ascentawits.<\/td><\/tr><tr><td><strong>Option\u2011Based Payments<\/strong><\/td><td>Upon exercising an option, Hisun will pay an agreed fee for each individual drug under development.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Access<\/strong> \u2013 The agreement gives Hisun a foothold in the rapidly expanding Chinese therapeutic market with a high\u2011potential oncology candidate.<\/li>\n\n\n\n<li><strong>Innovation Synergy<\/strong> \u2013 Leveraging Ascentawits\u2019 AKR1C3 platform could accelerate the development of a broader pipeline of small\u2011molecule therapeutics for Hisun.<\/li>\n\n\n\n<li><strong>Financial Flexibility<\/strong> \u2013 The capped milestone structure limits upfront risk while providing upside potential tied to commercial performance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600267_20250917_G7G7.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600267_20250917_G7G7.\"><\/object><a id=\"wp-block-file--media-4bd67d23-8796-4d3c-bb85-4a7e89322830\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600267_20250917_G7G7.pdf\">600267_20250917_G7G7<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600267_20250917_G7G7.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4bd67d23-8796-4d3c-bb85-4a7e89322830\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":41702,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4358,766,25,1466],"class_list":["post-41696","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascentawits-pharmaceuticals","tag-hisun-pharmaceutical","tag-potential-first-in-class","tag-sha-600267"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=41696\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=41696\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-17T07:07:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-17T07:11:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424\",\"datePublished\":\"2025-09-17T07:07:33+00:00\",\"dateModified\":\"2025-09-17T07:11:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696\"},\"wordCount\":255,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1708.webp\",\"keywords\":[\"Ascentawits Pharmaceuticals\",\"Hisun Pharmaceutical\",\"Potential first-in-class\",\"SHA: 600267\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41696#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=41696\",\"name\":\"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1708.webp\",\"datePublished\":\"2025-09-17T07:07:33+00:00\",\"dateModified\":\"2025-09-17T07:11:26+00:00\",\"description\":\"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=41696\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1708.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/1708.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=41696#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424 - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=41696","og_locale":"en_US","og_type":"article","og_title":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424","og_description":"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.","og_url":"https:\/\/flcube.com\/?p=41696","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-17T07:07:33+00:00","article_modified_time":"2025-09-17T07:11:26+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=41696#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=41696"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424","datePublished":"2025-09-17T07:07:33+00:00","dateModified":"2025-09-17T07:11:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=41696"},"wordCount":255,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=41696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","keywords":["Ascentawits Pharmaceuticals","Hisun Pharmaceutical","Potential first-in-class","SHA: 600267"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=41696#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=41696","url":"https:\/\/flcube.com\/?p=41696","name":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=41696#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=41696#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","datePublished":"2025-09-17T07:07:33+00:00","dateModified":"2025-09-17T07:11:26+00:00","description":"Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) announced today that it has signed an exclusive product\u2011licensing and strategic\u2011cooperation agreement with Shenzhen Ascentawits Pharmaceuticals Ltd. Under the deal, Hisun will introduce AST\u20113424, a first\u2011in\u2011class small\u2011molecule prodrug, into Mainland China, Hong\u202fKong SAR and Macao SAR.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=41696#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=41696"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=41696#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","width":1080,"height":608,"caption":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=41696#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hisun Pharma Secures China Rights to Ascentawits\u2019 First\u2011In\u2011Class Drug AST\u20113424"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/1708.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=41696"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41696\/revisions"}],"predecessor-version":[{"id":41703,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/41696\/revisions\/41703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/41702"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=41696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=41696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=41696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}